Navigation Links
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Date:1/8/2014

MOUNTAIN VIEW, Calif., Jan. 8, 2014 /PRNewswire/ -- The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.

New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Despite the popularity of VEGF inhibitors in the U.S., issues of patient preference and compliance, the risk of infection, as well as side effects such as floaters, increased intraocular pressure and inflammation of the eye exist," said Frost & Sullivan Life Sciences Senior Industry Analyst Debbie Toscano. "There is also a lack of substantive long term data on the ability of VEGF therapy to prevent visual impairment."

In addition, the rapid uptake of low-cost Avastin, supplied by compounding pharmacies, is challenging the VEGF inhibitors market. Although the U.S. Food and Drug Administration has drawn attention to safety issues with compounding pharmacies, physicians are accustomed to the inherent risks associated with using compounded Avastin, and patients too value the affordability of the drug.

"Regardless of the widespread off-label usage of Avastin for retinal diseases, there is still significant scope for market penetration through innovative formulations and drug delivery methods," pointed out Toscano. "For instance, market participants could roll out add-on therapies which can be combined with any VEGF inhibitor to boost efficacy. New treatments that can be administered orally or topical drops too would revolutionize treatment and garner significant market adoption in place of intravitreal injections."

Analysis of the US Retinal Therapeutics Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Analysis of the Global Type 2 Diabetes Therapeutics Market, Global Analysis of MicroRNA Tools and Services Market, Global Pharmaceutical Contract Manufacturing Market, and Breakthroughs in Ophthalmic Devices and Drug Delivery Technologies. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Analysis of the US Retinal Therapeutics Market
NC77-52

Contact:
Jennifer Carson
Corporate Communications – North America
P: 210.247.2450
E: jennifer.carson@frost.com

LinkedIn: Transform Health Group
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intra-Cellular Therapies Cleared for Quotation on OTCQB
2. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
3. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
4. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
7. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
8. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
9. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
10. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
11. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
(Date:5/3/2016)... -- As a teenager, an active and athletic Randy ... heart. He continued enjoying sports and recreation throughout his ... was giving out and he was a few hours ... Mesa, Arizona resident received a ... transplant, the SynCardia TAH-t is the only approved device ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... surgery at their office. Wisdom tooth removal, a common dental procedure, is performed for ... often are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal ...
(Date:5/4/2016)... Charlotte, NC (PRWEB) , ... May 04, 2016 , ... ... Charlotte, N.C., changed her life forever with a same-day LASIK procedure at ... to poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , ... called UTIs, have plagued people since the beginning of recorded medical history, and ... infections every year. It's not just a matter of inconvenience; bladder infections cost us ...
(Date:5/4/2016)... ... 04, 2016 , ... DESCO Medical Service, also known as ... sterilization service and sales company located in Pennsylvania. The terms of the deal ... asset management services to the medical and academic research industries. The acquisition will ...
Breaking Medicine News(10 mins):